The effect of the polymorphism in IL-28B gene on the treatment response of a combined therapy by sofosbuvir and daclatasvir with and without ribavirin in HCV Egyptian patients
Mahmoud, E., Abdel-Rasoul, H., Abdallah, E., Hassan, E. (2023). The effect of the polymorphism in IL-28B gene on the treatment response of a combined therapy by sofosbuvir and daclatasvir with and without ribavirin in HCV Egyptian patients. EKB Journal Management System, 11(1), 11-18. doi: 10.21608/fumj.2023.278457
Eman E. Mahmoud; Hoiyda A. Abdel-Rasoul; Eriny H. I. Abdallah; Essam A. Hassan. "The effect of the polymorphism in IL-28B gene on the treatment response of a combined therapy by sofosbuvir and daclatasvir with and without ribavirin in HCV Egyptian patients". EKB Journal Management System, 11, 1, 2023, 11-18. doi: 10.21608/fumj.2023.278457
Mahmoud, E., Abdel-Rasoul, H., Abdallah, E., Hassan, E. (2023). 'The effect of the polymorphism in IL-28B gene on the treatment response of a combined therapy by sofosbuvir and daclatasvir with and without ribavirin in HCV Egyptian patients', EKB Journal Management System, 11(1), pp. 11-18. doi: 10.21608/fumj.2023.278457
Mahmoud, E., Abdel-Rasoul, H., Abdallah, E., Hassan, E. The effect of the polymorphism in IL-28B gene on the treatment response of a combined therapy by sofosbuvir and daclatasvir with and without ribavirin in HCV Egyptian patients. EKB Journal Management System, 2023; 11(1): 11-18. doi: 10.21608/fumj.2023.278457

The effect of the polymorphism in IL-28B gene on the treatment response of a combined therapy by sofosbuvir and daclatasvir with and without ribavirin in HCV Egyptian patients

Fayoum University Medical Journal
Volume 11, Issue 1, January 2023, Page 11-18  XML PDF (611.62 K)
Document Type: Full Length research Papers
DOI: 10.21608/fumj.2023.278457
View on SCiNiTO View on SCiNiTO
Authors
Eman E. Mahmoud1; Hoiyda A. Abdel-Rasoul2; Eriny H. I. Abdallah email 3; Essam A. Hassan4
1Clinical and chemical pathology department, Fayoum university.
2Department of Clinical and Chemical Pathology, Faculty of Medicine, Fayoum University, Fayoum, Egypt.
3Department of clinical and chemical pathology, Faculty of medicine, Fayoum University, Fayoum, Egypt.
4Tropical medicine departemt, Fayoum university.
Abstract
Introduction: HCV infection is a universal health condition. Polymorphisms at the interleukin 28B (IL28B) gene severely affect treatment results to direct-acting antiviral drugs (DAA), including Sofosbuvir and
Daclatasvir with or without Ribavirin. The relationship between the virus and the host immune system is
critical for revealing the prognosis and the response to medications.
Aim of our study: It aimed to reveal if there is an association between the SNP of the IL-28B
(rs12979860) gene and hepatitis C virus treatment response to DAA in an Egyptian population.
Subjects and methods: This case-control descriptive analytical thesis contains 200 subjects, 100 HCV
patients who received Sofosbtuvir, Dacatasvir ± Ribavirin (50responders&50 non-responders) compared to
100 age and sex-matched healthy control subjects. Diseased people were recruited from the Tropical clinic
in Fayoum University Hospital from May 2019 to February 2020. All samples were subjected to genomic
DNA analysis of SNP of the IL-28B gene (rs12979860) using Real-Time PCR.
Results: The SNP IL-28B gene (rs12979860) was not statistically significantly different between HCVdiseased people compared to healthy subjects (P > 0.05). The c allele was also higher among drugresponsive patients, while the T allele was higher among drug-resistant patients (P <0.01), which is a highly
statistically significant difference.
Conclusion: The study showed a significant relation between IL-28Bgene (rs12979860) polymorphism and
hepatitis C virus treatment response to DAA. CC genotype is a significant indicator of SVR in HCV
genotype 4 Egyptian patients, and this genotype may influence the effectiveness of treatment.
 
Keywords
IL-28B gene; polymorphism; sustained virological response
Statistics
Article View: 100
PDF Download: 154